CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 01/06/22

– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib – – Expecting Key Data Readouts for Oral Fadraciclib in 2022 – – Planning to Launch Two Registration-Directed Studies for Diffe...

BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in...

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Mark Kirschbaum - Senior Vice President...

Cyclacel Pharmaceuticals (NASDAQ:CYCC): Q3 GAAP EPS of -$0.47 beats by $0.23. Press Release As of September 30, 2021, cash and cash equivalents totaled $40.2M, compared to $43.6M as of June 30, 2021. For further details see: Cyclacel Pharmaceuticals EPS beats by $0.23

- Second Phase 1/2 Study of Fadraciclib Now Enrolling Patients in Leukemia - - Cash Runway to Early 2023 - - Conference Call Scheduled November 10, 2021 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc....

OTCQX:ACRGF, ADMA, AEVA, DADAAMPE, AMWL, APP, APPH, ASND, ATO, OTCPK:ATUSF, AZUL, BANX, BARK, BIOL, BKEP, BMBL, BOXL, BRFS, BRKS, BROS, BSQR, BW, BYND, BZH, CBAY, CCCS, CCMP, CGRN, CLSD, CLVR, CRCT, CYCC, DARE, DGII, DIS, EDRY, EGLX, ELMS, ENS, EVOK, FICO, FIGS, FOSL, FSM, GAU, GDRX, GEVO, OT...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) announces the dosing of the first patient in the company’s multi-cohort Phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes (MDS). The Phase 1/2 registration-directed trial, designated CYC065-102, uses a str...

BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Company...

BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results a...

Cyclacel is a biotech company developing small molecule drugs for treating cancer and other diseases. CEO Spiro Rombotis joined us for a discussion about cancer resistance and clinical trials. Investor updates including recent study of oral Fadraciclib in patients with advanced tu...